Novo Nordisk said on Tuesday its next-generation experimental drug, CagriSema, showed 25% weight loss on average in women with obesity or overweight, according ​to data analyzed after the completion of a late-stage study.

Log in or sign up to comment.

No comments yet.

← Back to stories

Create FREE account

or login to continue

Signup with GoogleSignup with GitHubSignup with BlueskySignup with Blacksky
Sign up with email

Already have an account? Log in